文献速递妇科

自噬相关p62(SQSTM1)在多药耐药卵巢癌中的表达与作用

Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-04-24

该研究通过免疫组化检测卵巢癌组织芯片中p62表达,发现转移灶和复发灶p62表达低于配对原发灶,且p62表达与无病生存和总生存呈显著负相关;多药耐药细胞系p62表达低于亲本敏感细胞系,抑制自噬可增强紫杉醇敏感性并减少耐药细胞迁移。

要点

  • 转移灶和复发灶的p62表达低于患者配对的原发灶。
  • p62表达与无病生存和总生存均呈显著负相关。
  • 抑制自噬可增强耐药卵巢癌细胞对紫杉醇的敏感性并减少迁移。

核心结论

  • p62有潜力作为卵巢癌患者新的预后标志物,其相关自噬通路可能是预防转移、复发及逆转耐药的有前景的治疗靶点。

研究设计与样本

  • 研究采用免疫组化检测由配对原发、转移和复发肿瘤组织构建的卵巢癌组织芯片中p62表达。
  • 用蛋白质印迹法在两套人癌细胞系中评估p62及自噬相关蛋白表达水平。
  • 卵巢癌细胞暴露于不同浓度紫杉醇单用或联合自噬抑制剂后,用MTT法测定细胞活力。

主要发现

  • 转移和复发肿瘤组织的p62表达均低于患者配对的原发肿瘤。
  • p62表达与无病生存和总生存均呈显著负相关。
  • 多药耐药癌细胞系的p62表达水平低于其亲本药物敏感细胞系。
  • 抑制自噬增强了耐药卵巢癌细胞对紫杉醇的敏感性。
  • 划痕实验显示抑制自噬显著降低了耐药卵巢癌细胞的体外迁移。

临床怎么用

  • 作者认为p62有潜力作为卵巢癌患者新的预后标志物。
  • 作者认为p62相关自噬通路可能是预防转移、复发及逆转卵巢癌耐药的有前景的治疗靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Multidrug resistance is the major cause of treatment failure in ovarian cancer. p62 (SQSTM1) is a multifunctional protein involved in multiple cellular processes including proliferation, drug sensitivity and autophagy-associated cancer cell growth. However, the role of p62 in drug resistance remains controversial. METHODS: In this study, we examined p62 expression by immunohistochemistry in a unique ovarian cancer tissue microarray (TMA), which was constructed with paired primary, metastatic, and recurrent tumor tissues. The expression levels of p62 and autophagy related proteins were evaluated in two panels of human cancer cell lines by western blot. Cell viabilities were determined by MTT assay after exposure ovarian cancer cells to different concentrations of paclitaxel alone or in combination with autophagy inhibitors. RESULTS: Both the metastatic and recurrent tumor tissues expressed less p62 than the patient-matched primary tumor. A significant inverse correlation has been found between p62 expression and both the disease-free survival and overall survival. Additionally, multidrug resistant cancer cell lines expressed lower levels of p62 as compared with their parental drug sensitive cell lines. Importantly, inhibition of autophagy enhanced paclitaxel sensitivity in drug resistant ovarian cancer cells. Furthermore, the wound healing assay exhibited that the inhibition of autophagy significantly decreased resistant ovarian cancer cell migration in vitro. CONCLUSION: Our findings highlight the potential of p62 as a new prognostic marker for ovarian cancer patients and p62's associated autophagy pathway may be a promising therapeutic target to prevent metastasis, recurrence and to reverse drug resistance in ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Garbutt C, Ma H, et al. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. Gynecol Oncol. 2018. PMID: 29699801. doi:10.1016/j.ygyno.2018.04.557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。